Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Sales of Investments

Cash received from selling or redeeming investments.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Sales of Investments · Q4 FY2024 · quarter ended Dec 2024

Sales of investments outflow grows to $0

Q4 FY2024 sales of investments was $0, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $0. Over 3 fiscal years it compounded at +106.0% a year.

Context

  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2024
$0— QoQ
Last fiscal yearDec 2025
$16.87M— YoY
LTMDec 2024
$0— YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR+106.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
16.87M USD
Year-over-year change
—
4-year CAGR
+124.5%

Sales of Investments vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +106.0% compares with a peer median of -5.4%.
MENS Competitors
Sales of Investments for MENS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B USD-79.1%+105.5%75.2%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$871.69M USD+2.5%—14137.0%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$818.03M USD+32.8%+30.6%—
CNTACentessa Pharmaceuticals plcLTM Mar 2026$709.09M USD+238.3%——
APGEApogee Therapeutics, Inc.LTM Jun 2026$544.88M USD+24.1%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$395.01M USD-5.6%-6.6%59.0%
CELCCelcuity Inc.LTM Jun 2026$300.77M USD-48.0%——
TVTXTravere Therapeutics, Inc.LTM Sep 2026$246.48M USD-16.8%-5.4%37.9%
DYNDyne Therapeutics, Inc.LTM Jun 2026$157.88M USD-17.7%-6.6%—
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024$0 USD—+106.0%—
AAPGAscentage Pharma Group InternationalFY2025CN¥0 CNY——0.0%
Peer median (excluding MENS) —-5.6%-5.4%59.0%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Depreciation & Amortization122K123K127K120K100K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.24M2.94M1.12M(1.49M)20.74M
Accounts Receivables00000
Inventory00000
Accounts Payables21K(28K)(2K)1K(1K)
Other Working Capital1.22M2.97M1.12M(1.49M)20.74M
Other Non-Cash Items849K599K554K761K(19.21M)
Operating Cash Flow(1.98M)(2.97M)(2.6M)(3.62M)(3.04M)
Capital Expenditures(137K)(246K)000
Acquisitions (Net)00000
Purchases of Investments(1.83M)(292K)00(16.87M)
Sales of Investments664K1.93M95K016.87M
Other Investing Activities0000(13.51M)
Investing Cash Flow(1.31M)1.39M95K0(13.51M)
Debt Repayment(1.35M)3.61M2.47M2.2M(24K)
Common Stock Issued000017.77M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(35K)(276K)(445K)(213K)(114K)
Financing Cash Flow(1.38M)3.33M2.03M1.99M17.63M
Effect of Forex Changes67K(31K)(54K)(7K)(8K)
Net Change in Cash(4.61M)1.72M(532K)(1.64M)1.08M
Free Cash Flow(2.12M)(3.22M)(2.6M)(3.62M)(3.04M)

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.